How to buy Bristol-Myers Squibb Company (BMY) shares in Australia

Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$58.23. During the previous open market day, the price has varied from a low of USD56.095 to a high of USD58.65. Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.

Have Bristol-Myers Squibb Company's shares ever split?

Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before the split, the next day you would own 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.

Bristol-Myers Squibb Company shares at a glance

52-week range	US$38.6043 - US$61.08
50-day moving average more info button	US$52.407
200-day moving average more info button	US$48.216
Target price	US$58.6418
PE ratio more info button	N/A
Dividend yield more info button	US$2.4 (4.11%)
Earnings per share (TTM) more info button	US$-3.58

Bristol-Myers Squibb Company share growth calculator

Investment amount

US$

Investment period Choose a point in time from the list 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago 2 years ago 3 years ago 5 years ago

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Bristol-Myers Squibb Company price performance over time

Historical closes compared with the last close of $58.23

Compare trading platforms to buy Bristol-Myers Squibb Company shares

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Bristol-Myers Squibb Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bristol-Myers Squibb Company share price volatility

Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$38.6043 up to US$61.08. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.441. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).

Bristol-Myers Squibb Company financials

Revenue TTM	US$47.4 billion
Operating margin TTM	18.48%
Gross profit TTM	US$36.4 billion
Return on assets TTM	6.07%
Return on equity TTM	-31.33%
Profit margin	-15.3%
Book value	8.453
Market capitalisation more info button	US$118.6 billion
EBITDA more info button	US$19.2 billion

TTM: trailing 12 months

Bristol-Myers Squibb Company share dividends

Dividend payout ratio: 2.26% of net profits

Recently Bristol-Myers Squibb Company has paid out, on average, around 2.26% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.11% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 4.11% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.4 per share.

While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.

Bristol-Myers Squibb Company's most recent dividend payout was on 31 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2024 (the "ex-dividend date").

Bristol-Myers Squibb Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bristol-Myers Squibb Company's total ESG risk score

Total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bristol-Myers Squibb Company's environmental score

Environmental score: 3.83/100

Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's social score

Social score: 18.82/100

Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bristol-Myers Squibb Company's governance score

Governance score: 14.02/100

Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score	29.16
Total ESG percentile	52.58
Environmental score	3.83
Environmental score percentile	4
Social score	18.82
Social score percentile	4
Governance score	14.02
Governance score percentile	4
Level of controversy	2

Bristol-Myers Squibb Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Frequently asked questions

• What percentage of Bristol-Myers Squibb Company is owned by insiders or institutions?

  Currently 0.115% of Bristol-Myers Squibb Company shares are held by insiders and 78.478% by institutions.

• When does the fiscal year end for Bristol-Myers Squibb Company?

  Bristol-Myers Squibb Company's fiscal year ends in December.

• Where is Bristol-Myers Squibb Company based?

  Bristol-Myers Squibb Company's address is: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

• What is Bristol-Myers Squibb Company's ISIN number?

  Bristol-Myers Squibb Company's international securities identification number is: US1101221083

• What is Bristol-Myers Squibb Company's CUSIP number?

  Bristol-Myers Squibb Company's Committee on Uniform Securities Identification Procedures number is: 110122108